文献速递免疫规划妇幼与学校卫生

产前母亲接种COVID-19疫苗与妊娠结局的回顾性队列研究

Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
PubMed 文献 · Vaccine · 2021-09-07

该回顾性队列研究纳入2021年1月至6月在以色列Soroka大学医学中心分娩的4399名妇女,其中913名(20.8%)在妊娠中晚期接种了辉瑞-BioNTech COVID-19疫苗。粗分析和多变量调整后,接种组与未接种组在妊娠、分娩及新生儿并发症方面均无差异。结论认为产前接种该疫苗对妊娠过程和结局无不良影响。

要点

  • 产前接种辉瑞-BioNTech COVID-19疫苗未增加妊娠、分娩及新生儿并发症风险。
  • 所有接种均发生在妊娠中晚期,早孕期接种数据未涉及。
  • 接种组与未接种组在分娩孕周、小于胎龄儿及新生儿呼吸并发症上无差异。

核心结论

  • 产前母亲接种辉瑞-BioNTech COVID-19疫苗对妊娠过程和结局无不良影响。

研究设计与样本

  • 回顾性队列研究,纳入2021年1月至6月在以色列Soroka大学医学中心分娩的所有妇女,排除既往COVID-19诊断、多胎妊娠或疫苗接种状态不详者,最终分析4399名妇女,其中913名(20.8%)在孕期接种疫苗。

主要发现

  • 接种组与未接种组在妊娠、分娩和新生儿并发症(包括分娩孕周、小于胎龄儿发生率和新生儿呼吸并发症)方面,粗分析和多变量分析均未发现差异。
  • 接种组妇女年龄更大、更可能通过生育治疗受孕、产前保健更充分且社会经济地位更高。
  • 所有疫苗接种均发生在妊娠中晚期。

临床怎么用

  • 研究结果可帮助孕妇和医疗保健提供者就接种COVID-19疫苗做出知情决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prenatal maternal physiological changes may cause severe COVID-19 among pregnant women. The Pfizer-BioNTech COVID-19 vaccine (BNT162b2 mRNA) has been shown to be highly effective and it is recommended for individuals aged ≥16 years, including pregnant women, although the vaccine has not been tested on the latter. OBJECTIVE: To study the association between prenatal Pfizer-BioNTech COVID-19 vaccination, pregnancy course and outcomes. STUDY DESIGN: A retrospective cohort study was performed, including all women who delivered between January and June 2021 at Soroka University Medical Center, the largest birth center in Israel. Excluded were women diagnosed with COVID-19 in the past, multiple gestations or unknown vaccination status. Pregnancy, delivery and newborn complications were compared between women who received 1 or 2-dose vaccines during pregnancy and unvaccinated women. Multivariable models were used to adjust for background characteristics. RESULTS: A total of 4,399 women participated in this study, 913 (20.8%) of which were vaccinated during pregnancy. All vaccinations occurred during second or third trimesters. As compared to the unvaccinated women, vaccinated women were older, more likely to conceive following fertility treatments, to have sufficient prenatal care, and of higher socioeconomic position. In both crude and multivariable analyses, no differences were found between the groups in pregnancy, delivery and newborn complications, including gestational age at delivery, incidence of small for gestational age and newborn respiratory complications. CONCLUSIONS: Prenatal maternal COVID-19 vaccine has no adverse effects on pregnancy course and outcomes. These findings may help pregnant women and health care providers to make informed decision regarding vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wainstock T, Yoles I, Sergienko R, et al. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine. 2021. PMID: 34531079. doi:10.1016/j.vaccine.2021.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。